Struggling GSK inks a translational deal with QB3

San Francisco incubator QB3 is linking up with pharma giant GlaxoSmithKline ($GSK) on some translational work, looking to push a few academic research projects toward the clinic. [email protected] will work with the folks at GSK to find some promising collaborations to work on. This is the latest in a long lineup of discovery deals for GlaxoSmithKline, which set up its Discovery Partnerships with Academia (DPAc) team to find promising new programs. GSK may be busy in the early-stage field, but it's been losing the interest of Wall Street analysts who are distinctly not excited by its weak set of late-stage prospects. Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.